4J Therapeutics, Inc., is a biopharmaceutical company focused on the development of novel, broad-spectrum antiviral agents for the treatment of influenza and other serious viral infections using a unique programmable antiviral platform approach. This strategy employs the rapid identification and subsequent design of potent pre-exposure and post-infection antiviral therapeutics against highly conserved RNA secondary structure targets in viruses of public health concern. Our pipeline includes preclinical NCEs shown to possess antiviral activity against influenza A virus and other viruses of major medical importance and pandemic potential.